OptimizeRx agreed to acquire 100% of Medicx Health. The operation will be funded through a combination of existing cash, short-term investments, and proceeds from a new $40 million credit facility provided by Blue Torch Capital. Certain members of Medicx's management, including founder and CEO, committed to reinvesting approximately $10.5 million of their transaction proceeds into OptimizeRx common stock, aligning their interests with the combined entity's success. The strategic rationale centres on creating the most comprehensive healthcare marketing platform in the US by combining OptimizeRx's HCP-focused DAAP platform with Medicx's consumer-focused Micro-Neighborhood® Targeting Platform — thereby addressing both key stakeholders in pharmaceutical marketing (doctors and patients) through a single integrated technology ecosystem.

MEDICX HEALTH, which reported an EBITDA margin of LOGIN in 2022, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the TMT (Tech, Media, Telecom) sector (12.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.